Lowers the risk of cardiovascular death and hospitalization for heart failure. ANDA 213748, held by MSN Laboratories. Sacubitril; Valsartan.
As of Nov 21, 2026, ANDA 213748 (Sacubitril and Valsartan), held by MSN Laboratories, was first approved by FDA on Jul 16, 2025, with 0 approved supplements and 0 published complete response letters.
Sacubitril and valsartan tablets are a combination of sacubitril, a neprilisin inhibitor, and valsartan, an angiotensin II receptor blocker, and is indicated: to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure and reduced ejection fraction. for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan tablets reduces NT-proBNP and is expected to improve cardiovascular outcomes. 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 16, 2025 | Original application | Approved |
| Sacubitril and Valsartan24MG;26MG · tablet;oral | Sacubitril; Valsartan | Rx |
| Sacubitril and Valsartan49MG;51MG · tablet;oral | Sacubitril; Valsartan | Rx |
| Sacubitril and Valsartan97MG;103MG · tablet;oral | Sacubitril; Valsartan | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters